Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A target identification team-up
January 2017
SHARING OPTIONS:

BILLERICA, Mass.—A set of agreements has been announced between MilliporeSigma and Evotec AG, under which the latter will provide screening services for Merck KGaA’s genetic reagents, such as CRISPR and shRNA libraries. Customers will be able to choose a customized set of CRISPR and shRNA libraries and apply Evotec’s offerings in phenotypic screening within primary and induced pluripotent stem cells and in-vivo disease models. Target identification options are also boosted through the use of custom-engineered cell lines developed via MilliporeSigma’s Cell Design Studio, cell lines that Evotec uses to customize screening assays.
“Drug discovery starts with the identification of new targets, a process that can be time- and labor-intensive,” said Theresa Creasey, head of Applied Solutions Strategic Marketing & Innovation at MilliporeSigma. “Our collaboration with Evotec accelerates the discovery workflow, enabling customers to more rapidly and efficiently explore disease pathways and find new targets.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.